Objective: In vitro measurements of cholesterol efflux from macrophages have recently been shown to associate with cardiovascular risk. We investigated whether cholesterol efflux from macrophages incubated with plasmas from overweight/ obese subjects with metabolic syndrome was influenced by the presence of insulin resistance. Methods: Plasmas were obtained from 47 men and women with metabolic syndrome, of whom 25 were found to be insulin resistant (IR) and 22 insulin sensitive (IS) (Matsuda, De Fronzo equation based on oral glucose tolerance test). Activated human macrophage THP-1 cells in which cholesterol had been radiolabelled were incubated with the subjects' plasmas to allow calculation of % cholesterol efflux. Results: Body mass index and waist measurements, as well as plasma lipid levels, did not differ between the two groups. Homeostatic model assessment-insulin resistance value as well as plasma insulin and leptin concentrations were higher in IR subjects. Cholesterol efflux was found to be significantly greater with plasmas from IR subjects (9.1%) than from IS subjects (6.7%) (P ¼ 0.005). Further, cholesterol efflux was significantly inversely associated with insulin sensitivity index (Po0.001), directly with arterial insulin concentration (Po0.001) and directly with cholesteryl ester transfer protein (CETP) mass (P ¼ 0.044). Conclusion: Plasmas from overweight subjects with insulin resistance induced greater in vitro cholesterol efflux compared with IS subjects. Efflux inversely correlated with insulin sensitivity suggesting an increase in reverse cholesterol transport in the IR state that may lead to greater transfer of cholesterol to apoB lipoproteins from high-density lipoproteins via CETP as a factor in the association between IR and atherosclerosis.
Introduction
Measurements of reduced cholesterol efflux from macrophages have recently been shown in cells incubated with apolipoprotein B-depleted plasmas from patients with evidence of atherosclerosis-related thickening of carotid artery intima-media or angiographically proven coronary artery disease. 1 Although such plasmas contained predominantly high-density lipoproteins (HDL), HDL was found to determine less than half the capacity of plasma to stimulate efflux. 1 Cholesterol efflux measured in vitro has also been found to be diminished when cells were incubated with plasma or isolated apolipoprotein A-I from type 2 diabetic subjects. Syvanne et al. 2 found that plasmas from diabetic men especially if they also suffered from coronary artery disease induced a diminished efflux from Fu5AH hepatoma cells. Further, the usual positive relationship between LpA-I concentration in plasma and efflux was absent, although such an association did exist between efflux and LpA-I:A-II HDL particles. Cavallero et al. 3 incubated ob1771 cells (a preadipocyte line) with LpA-I isolated by immunoaffinity chromatography, and also reported that LpA-I isolated from plasmas of subjects with type 2 diabetes induced a lesser efflux of cholesterol than that from healthy subjects. LpA-I:A-II are generally found in smaller HDL that predominate in plasmas of subjects with insulin resistance such as in those with metabolic syndrome and diabetes. 4 We have also reported previously in subjects with metabolic syndrome and elevated plasma insulin concentration an apparently paradoxical inverse correlation between LpA-I and cholesterol efflux, which was suggestive of dysfunctional large HDL. 5 In these subjects with insulin resistance (IR), the concentration of smaller LpA-I:A-II-associated HDL was more than twice that of LpA-I particles. 5 Cholesterol efflux from macrophages accounts for only a minor part of total reverse cholesterol transport (RCT) from tissues to the liver although even that small fraction may be highly relevant to atherosclerosis. 6 Cholesterol efflux is recognised as the initial step in RCT that generates small HDL particles (preb-1 HDL) with subsequent esterification of the free cholesterol by lecithin cholesterol acyl transferase (LCAT) and redistribution of esterified cholesterol among lipoproteins by cholesteryl ester transfer protein (CETP). When cells are incubated with whole plasma, there are several key factors other than HDL particles that may influence efflux. There is a substantial difference in efflux between incubations with whole plasma and apolipoprotein B-depleted plasma indicating that apolipoprotein B-containing lipoproteins, which are elevated in subjects with metabolic syndrome and diabetes, may act as a sink for cholesteryl esters. The activity of plasma LCAT has been reported to be elevated in patients with insulin resistance, 7 and CETP, which leads to the transfer of cholesteryl esters from HDL to apolipoprotein B-containing lipoproteins, has also been shown to be elevated in patients with insulin resistance and hypertriglyceridemia. 8 Further, an activator of CETP production, anacetrapib, increases cholesterol efflux at least in vitro. 9 Thus, a number of critical factors subserving RCT appear to be increased in plasmas of subjects with insulin resistance. Thus, it may appear paradoxical that whereas several steps in the RCT pathway are increased in subjects with insulin resistance, measurements of cholesterol efflux at least in vitro are lower in subjects with cardiovascular disease and diabetes than in healthy individuals. As not all subjects with the characteristics of the metabolic syndrome are IR, we tested the hypothesis that plasmas from these two groups of subjects whose plasma insulin concentration would differ may induce cholesterol efflux differentially. We have recently reported on the effects of weight reduction on insulin sensitivity and sympathetic nerve activity. 10 We now report the effect of incubating plasmas from these subjects with cholesterol-loaded activated macrophages (THP-1 cells) related to the arterial insulin concentration, to whole-body insulin sensitivity derived from an oral glucose tolerance test (OGTT) and to CETP mass.
Subjects and methods

Subjects
A total of 47 men and women who fulfilled the criteria for metabolic syndrome (excess waist circumference and two additional metabolic abnormalities as defined by the National Cholesterol Education Adult Treatment Panel III
)
were recruited through advertisement. None of the subjects had been receiving treatment for hypertension within the previous 6 weeks, and none for dyslipidemia. Diabetic patients were excluded, as were any with abnormal hepatic, thyroid or renal function. None smoked, and alcohol intake was limited to not more than two standard drinks daily. Plasmas were collected from subjects in the fasting state (410 h) on the day when the OGTT was carried out, separated at 4 1C, and immediately frozen at À80 1C specifically for the in vitro cholesterol efflux experiments. Their habitual current food consumption patterns were assessed from 3-day food intake diaries and standard food frequency questionnaire; foods were converted to major macronutrient content from Australian Food Tables. Eating patterns were found to lie within the range of usual Australian diets that included a minority of vegetarians but no vegans.
Insulin sensitivity measurement A standard 75 g OGTT (Glucaid, Fronine Pty Ltd, Australia) was performed following an overnight fast, and blood samples were collected 30, 60, 90 and 120 min later for glucose and insulin concentrations. Whole-body insulin sensitivity was calculated from the OGTT parameters by the formula of Matsuda and DeFronzo. 12 
000=
p ððFPGÂFPIÞÂðmean glucoseÂmean insulinÞÞ where FPG is the fasting plasma glucose concentration in mg dl
À1
; FPI the fasting plasma insulin concentration in mU l
; mean glucose the average glucose concentration during OGTT (at times 0, 30, 60, 90 and 120 min) in mg dl
; and mean insulin the average insulin concentration during OGTT (at times 0, 30, 60, 90 and 120 min) in mU l
. This index represents a composite of both hepatic and peripheral tissue sensitivity to insulin, and has been validated against the euglycaemic hyperinsulinaemic clamp method in subjects with normal and impaired glucose tolerance. 12 We stratified subjects into insulin sensitive (IS) (42.1) and IR (o2.1), corresponding to insulin areas under the curve between times 0 and 120 min, of o10 000 and 410 000 mU l À1 Â min, respectively. This cutoff represents values in populations with normal and impaired glucose tolerance, respectively. 13 
Laboratory measurements
Samples of blood were obtained through an arterial line inserted into the brachial artery. Arterial plasma glucose was measured enzymatically (Architect C18000 analyzer, Abbott Laboratories, Abbott Park, IL, USA), insulin and leptin by radioimmunoassay (Linco Research, St Charles, MO, USA), plasma lipids on a Cobas analyzer (Roche Diagnostic Systems, Basel, Switzerland) and high-sensitivity C-reactive protein (hs-CRP) by an immunoturbidimetric assay. CETP mass, LCAT mass and the concentration of preb-1 HDL were
Insulin sensitivity influences cholesterol efflux P Nestel et al measured by respective enzyme-linked immunosorbent assay kits obtained from Sekisui Medical Co. Ltd, Tokyo, Japan. Inter-assay variability for both CETP and LCAT measurements were o4%.
Measurement of cholesterol efflux
Plasmas were collected after subjects had fasted overnight, and harvested in a cold centrifuge and frozen at À80 1C. H]-cholesterol (GE Healthcare, Buckinghamshire, UK). Cells were washed with phosphate-buffered saline, and further incubated for 18 h in serum-free medium containing 1 mM of the LXR agonist TO-901317 (Sigma, Sydney, New South Wales, Australia) to activate the ABCA1 transporter. Cells were further washed with serum-free medium containing the test plasmas at a final concentration of 2% for 2 h at 37 1C. Medium and cells were collected, and aliquots taken for counting of radioactivity. Cholesterol efflux was defined as the proportion of radioactivity in medium divided by radioactivity in medium þ cells. Background efflux, where efflux was to serum-free medium without cholesterol acceptor, was subtracted.
Statistical methods
Data are presented as means ± s.d. or s.e. as appropriate and statistical analyses performed using SigmaStat version 3.5. (Systat Software, Point Richmond, CA, USA). Differences between groups were analysed by the t-test or the MannWhitney Rank Sum Test. Associations between parameters were carried out using Pearsons correlation or Spearmans rank correlations with Po0.05 accepted as significant.
Ethics approval
Approval for the study was obtained from the Human Research Committee of the Alfred Hospital, Melbourne. Written consent was obtained from participants.
Results
Mean age was 53 ± 01 years; body mass index: 32.2 ± 0.6 kg m À2 and waist circumference exceeded 102 cm in the men and 88 cm in the women (106±1.4 cm for the group). Metabolic parameters are shown in Table 1 . Although the mean fasting plasma glucose concentration for the entire group was only slightly above normal, the fasting insulin level and homeostatic model assessmentinsulin resistance (HOMA-IR) were elevated on average clearly above normal. Mean plasma triglyceride concentration for the whole group was raised slightly, but HDL cholesterol was within the normal range and low-density lipoprotein cholesterol was elevated. Arterial insulin concentrations were significantly higher among subjects with insulin resistance (20.6, s.e. 0.8 mU l À1 ) versus those who were IS ((12.8, s.e. 0.8 mU l À1 ), Po0.001) ( Table 1) . Of the 47 subjects, 22 were found to be IS and 25 IR (mean insulin sensitivity index 3.14 versus 1.68, respectively). Both the insulin sensitivity index and HOMA-IR differed significantly between the two groups (Po0.001).
None of the lipid parameters differed significantly between IS and IR subjects. Plasma leptin concentration differed significantly being higher in the IR group.
Values for CETP mass and LCAT mass, and concentration of preb-1HDL concentration are shown in Table 2 and Figure 1 .
Correlations between cholesterol efflux and measures of insulin sensitivity, plasma lipids and other biomarkers associated with insulin resistance are shown in Table 3 .
Importantly, cholesterol efflux measured in vitro was found to be related to parameters of insulin sensitivity/ resistance derived from the OGTT carried out on the day that plasma was collected from the fasted subjects for the cell studies.
Arterial insulin concentration tended to be directly correlated with efflux (R ¼ 0.29, P ¼ 0.05), and log Insulin sensitivity index was inversely correlated with efflux (R ¼ À0.31, P ¼ 0.03). As expected, there was a strong inverse correlation between arterial insulin concentration and insulin sensitivity index (R ¼ À0.85, Po0.001), which remained highly significant on stepwise regression analysis that included also cholesterol efflux (Po0.001).However, neither arterial glucose (R ¼ 0.004) nor arterial HOMA-IR (R ¼ 0.25) correlated significantly with cholesterol efflux.
Cholesterol efflux correlated significantly but inversely with plasma apolipoprotein A-I concentration (R ¼ À0.36, P ¼ 0.015), but not with HDL-C (R ¼ 0.011) or any other lipid parameter. The inverse relationship between cholesterol efflux and apolipoprotein A-I concentration applied equally in subjects with insulin sensitivity and resistance (R ¼ À0.48 in both instances and Po0.03), although it should be noted that both groups showed other manifestations of the metabolic syndrome.
There were no significant associations between efflux and other metabolic parameters in plasma (with log leptin R ¼ 0.17, with log hs-CRP R ¼ 0.21).
Cholesterol efflux was not related to body mass index or to the waist/hip ratio. Interestingly, the intakes of total fat and of saturated fat were directly correlated with efflux.
The correlations between cholesterol efflux and CETP mass were positively significant for the whole group (R ¼ 0.30, P ¼ 0.044), and tended in the same direction for IR but not IS subjects (R ¼ 0.36, P ¼ 0.09). Cholesterol efflux appeared to be weakly correlated with preb-1 HDL in the IR group only (R ¼ 0.30, P ¼ 0.14). LCAT mass did not appear to be correlated with cholesterol efflux.
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Discussion
The major finding was that plasmas from subjects with insulin resistance elicited a significantly greater cholesterol efflux from activated human THP-1 cells, a macrophage line, than plasmas from IS subjects ( Table 2 and Figure 1 ). In the group as a whole, cholesterol efflux was inversely correlated with insulin sensitivity (Table 3) reflecting the greater efflux with plasmas derived from IR subjects. Arterial insulin concentration was almost significantly and directly associated with cholesterol efflux possibly only reflecting the expected inverse correlation between insulin sensitivity and insulin concentration demonstrated by stepwise regression analysis, which showed insulin sensitivity to be the major correlate with cholesterol efflux (inversely).
Of the three additional parameters of RCT that we measured, only CETP mass was significantly correlated with cholesterol efflux in the whole group (P ¼ 0.044), which appeared to be due to the stronger correlation for the plasmas from IR subjects (R ¼ 0.36). The concentration of preb-1 HDL in plasma was also found to correlate weakly with cholesterol efflux (R ¼ 0.30 for the IR group, P ¼ 0.14) but LCAT mass showed no correlation with efflux. Thus, there appeared to be support for increased RCT demonstrable in vitro subsequent to increased cholesterol efflux when the macrophages were incubated with plasmas from IR subjects. With respect to CETP mass we did not measure CETP activity Insulin sensitivity influences cholesterol efflux P Nestel et al although it is recognised that mass and activity tend to be significantly correlated. Several previous studies had reported diminished cholesterol efflux in vitro when cells were incubated with plasma or LpA-I derived from diabetic subjects 2, 3 , in contrast to the present study, which showed increased capacity of plasmas from IR subjects to support cholesterol efflux. Our study appears to be the first to have differentiated efflux capacity between plasmas from subjects with insulin resistance and insulin sensitivity. Both groups of subjects had documented metabolic syndrome, and in terms of body mass index, waist circumference and plasma lipids the two groups did not differ significantly. The subjects with insulin resistance showed significantly higher arterial insulin concentrations, greater HOMA-IR values and by definition substantially lower insulin sensitivity index (Table 1) . Thus, the concentrations of potential cholesterol acceptor lipoproteins to which the THP-1 cells were exposed in vitro (total HDL and apolipoprotein B lipoproteins) did not differ significantly. Of the measured parameters, only insulin and plasma leptin concentrations were higher in the plasmas from IR subjects with which the cells were incubated. Although dietary fat and in particular saturated fat consumption correlated directly and significantly with cholesterol efflux measured in vitro, this likely reflects the adverse effect on whole-body insulin sensitivity as we have reported in a similar group of overweight subjects. 13 Reports from other laboratories support the possibility that RCT, of which cholesterol efflux from cells is the initial step, is enhanced in subjects with insulin resistance, as occurs in the metabolic syndrome. The steps that follow cholesterol efflux and lead to the formation of preb-1 HDL, the activities of the cholesterol-esterifying enzyme LCAT 7 and CETP, the transporter of esterified cholesterol, resulting in the redistribution of that lipid among lipoproteins, 8 have both been reported to be elevated in subjects with insulin resistance. This suggests that the pathway of RCT is Insulin sensitivity influences cholesterol efflux P Nestel et al enhanced in such subjects. The final step, the excretion of cholesterol from the body is also higher in patients with obesity and potential insulin resistance.
14 Although we did not find a correlation between LCAT mass and cholesterol efflux, a study in 32 non-diabetic men found that LCAT activity was greater in the highest versus the lowest quartile of insulin resistance. 7 A link between LCAT activity in plasma and insulin resistance is also supported by the finding of significantly higher LCAT activity in 74 subjects with metabolic syndrome versus 90 healthy subjects (Po0.001). 15 In our study, we measured LCAT mass and not activity, and for LCAT, activity and mass do not necessarily correlate. Plasma CETP activity has been reported to be elevated in subjects with insulin resistance, diabetes, dyslipidemia and obesity. 9 CETP has a critical role in post-prandial lipidemia, 8 which is also greater in IR states associated with dyslipidemia. The increased CETP activity especially in dyslipidemia facilitates the transfer of cholesteryl esters from HDL to atherogenic triglyceride-rich lipoproteins and to low-density lipoprotein. It has been shown that apolipoprotein B lipoproteins can be direct acceptors of free cholesterol released from cells in vitro.
16
The importance of preb-1 HDL as a key mediator of ABCA1-mediated cholesterol efflux from macrophages in IR states was recently demonstrated by Attia et al., 17 who measured cholesterol efflux capacity in ABCA1-expressing J774 cells incubated with sera from obese subjects with insulin resistance. They concluded that the preb-1 HDL levels were the major determinants of efflux capacity. Further, preb-1 HDL concentrations rose to significantly higher levels following a fat meal in the overweight/obese compared with normal weight subjects. 17 Thus, there appears to be considerable support for key factors in the RCT system to be increased in concentration or activity in the IR state. Our study appears to be the first to show this for cholesterol efflux. We do not have an explanation for the apparent contradiction between the findings of increased RCT in IR subjects and that of diminished cholesterol efflux reported earlier for plasmas from diabetic subjects. 2, 3 Further, the first large-scale study of the capacity of plasmas (depleted of apoB lipoproteins) to support in vitro cholesterol efflux has shown to be diminished in patents with proven coronary artery disease or increased carotid intima-media thickening. 1 The authors
could not explain what factors beside HDL may have been deficient in the plasmas of those subjects as low HDL itself could not explain the findings. Whereas the plasmas used in our study contained apolipoprotein B as well as HDL, both lipoprotein species were of similar concentration in the IS and IR groups. Insulin concentrations were certainly higher among IR subjects, but we had previously found that adding insulin to plasma in vitro did not affect efflux (A Hoang, unpublished data). It is possible that insulin resistance initially induces increased RCT, which declines as atherothrombotic complications develop. Whether that reflects changes in the configuration or functionality of lipoprotein acceptors of cholesterol or to changes in other circulating factors is speculative. The inverse correlation between cholesterol efflux and the apolipoprotein A-I concentration in plasma, while possibly counterintuitive given the strong link between this apolipoprotein and ABCA1-mediated cholesterol efflux, resembles our previous report in similar subjects. 5 It is known that both HDL and LpA-I (the lipoprotein associated with large HDL) may be dysfunctional in subjects with metabolic syndrome, diabetes and coronary heart disease. 18 On the other hand, it may reflect the lesser capacity of smaller HDL such as those that comprise LpA-I:A-II particles to support efflux and the preponderance of this HDL species in these patients.
It is important to emphasise that we tested the plasmas and not the cells of these subjects. This is worth noting as individuals with ABCA1 mutations (that reduce cholesterol efflux) showed greater arterial intima-media thickness and their skin fibroblasts have been found to have lesser capacity for cholesterol efflux. 19 
Conclusions
Our findings cannot be interpreted beyond the possibility that increased cholesterol efflux capacity of plasma, albeit demonstrated only in vitro, is part of enhanced RCT in subjects with insulin resistance. Our interpretation is supported by our and other reports of raised CETP mass/ activity, and of preb-1 HDL concentration in overweight IR subjects. The consequent increased flux of cholesterol within HDL and its transfer to atherogenic apolipoprotein B lipoproteins may contribute to atherogenesis in this disorder.
